; or (B) determine that such indications for use are eligible for technology certification in accordance with section 587D(b)(2), or are otherwise exempt from premarket review under section 587B. (2) Process Any action under paragraph (1) shall be made by publication of a notice of such proposed action on the internet website of the Food and Drug Administration, the consideration of comments to a public docket on such proposal, and publication of a final action on such internet website within 60 calendar days of the close of the comment period posted to such public docket, notwithstanding subchapter II of chapter 5 of title 5, United States Code. (b) Revocation The Secretary may revoke any exemption with respect to such test or indications for use pursuant to section 587(10), if— (1) new clinical information indicates that the exemption of an in vitro clinical test or tests from premarket review under section 587B or exemption under section 587A has a reasonable probability of severe adverse health consequences, including the absence, delay, or discontinuation of appropriate medical treatment. (2) Process Any action under this subsection shall be made by publication of a notice of such proposed action in the Federal Register, consideration of comments to a public docket on such proposal, and publication of a final notice in the Federal Register, notwithstanding subchapter II of chapter 5 of title 5, United States Code. 587G. Advisory committees (a) In general The Secretary may establish advisory committees or use advisory committee panels of experts established before the date of enactment of this section for the purposes of providing expert scientific advice and making recommendations related to— (1) the approval of an application for an in vitro clinical test submitted under this subchapter, including for evaluating, as applicable, the analytical validity, clinical validity, and safety of in vitro clinical tests